A human SARS-CoV neutralizing antibody against epitope on S2 protein
Open accessAbstract
An immune antibody phage-display library was constructed from B cells of SARS convalescent patients. More than 80 clones were selected from the library by using the whole inactivated SARS-CoV virions as target. One human scFv, B1, was characterized extensively. The B1 recognized SARS pseudovirus in vivo and competed with SARS sera for binding to SARS-CoV with high affinity (equilibrium dissociation constant, K(d) = 105 nM). The B1 also has potent neutralizing activities against infection by pseudovirus expressing SARS-CoV S protein in vitro. Finally, we found that the B1 recognized an epitope on S2 protein, especially within amino acids 1023-1189 of S2 protein. This study not only first made a human neutralizing antibody, which recognized an epitope on S2 protein like natural antibody in sera, but also may help us to better understand the immunological characteristics of SARS protein and SARS vaccine design.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Targeting the RBD has been a major focus in COVID-19 vaccine development.
“Eliciting an immune response that targets the RBD has been a major focus of vaccine development on the assumption that antibodies that bind this critical domain can prevent viral entry into host cells, thereby allowing for sterilizing immunity (that is, the complete prevention of infection)152–154, which would support herd immunity if vaccine coverage is sufficiently high155.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · see citing works
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574 · see citing works
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Tg, K., Erdman, D. D., Cs, G., Zaki, Peret, T. C. T., Emery, S. L., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,345 · see citing works
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, M. J. S., Lai, S., Poon, L. L. M., Guan, Y., Yam, L., Lim, W., Nicholls, J. M., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,916 · see citing works
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R. S. M., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P. K. S., Wong, K. C., Leung, C. B., & Cheng, G. Y.-M. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 953 · see citing works
Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., & Virnekäs, B. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3444 · Cited by 728 · see citing works
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697 · see citing works
Wong, S. K., Li, W., Moore, M. J., Choe, H., & Farzan, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300520200 · Cited by 690 · see citing works
Simmons, G., Reeves, J. D., Rennekamp, A. J., Amberg, S. M., Piefer, A. J., & Bates, P. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306446101 · Cited by 543 · see citing works
Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 540 · see citing works
Soo, Y. O. Y., Cheng, Y., Wong, R. S. M., Hui, D. S. C., Lee, C. K., Tsang, K., Ng, M., Chan, P. K. S., Cheng, G. Y.-M., & Sung, J. J. �. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00956.x · Cited by 381 · see citing works
Exploiting recombination in single bacteria to make large phage antibody libraries
Sblattero, D., & Bradbury, A. M. (2000) · Nature Biotechnology · doi:10.1038/71958 · Cited by 317 · see citing works
Profile of Specific Antibodies to the SARS-Associated Coronavirus
Li, G., Chen, X., & Xu, A. (2003) · New England Journal of Medicine · doi:10.1056/nejm200307313490520 · Cited by 307 · see citing works
Protein absorption and ellipsometry in biomaterial research
Elwing, H. B. (1998) · Biomaterials · doi:10.1016/s0142-9612(97)00112-9 · Cited by 298 · see citing works
SARS coronavirus: a new challenge for prevention and therapy
Holmes, K. V. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18819 · Cited by 237 · see citing works
van den Brink, E. N., ter Meulen, J., Cox, F., Jongeneelen, M. A. C., Thijsse, A., Throsby, M., Marissen, W. E., Rood, P. M. L., Bakker, A. B. H., Gelderblom, H. R., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1635-1644.2005 · Cited by 155 · see citing works
Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S Protein
Giroglou, T., Cinatl, J., Rabenau, H., Drosten, C., Schwalbe, H., Doerr, H., & von Laer, D. (2004) · Journal of Virology · doi:10.1128/jvi.78.17.9007-9015.2004 · Cited by 147 · see citing works
He, Y., Zhou, Y., Wu, H., Luo, B., Chen, J., Li, W., & Jiang, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4050 · Cited by 142 · see citing works
Song, H. C., Seo, M. Y., Stadler, K., Yoo, B. J., Choo, Q., Coates, S. R., Uematsu, Y., Harada, T., Greer, C. E., Polo, J. M., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10328-10335.2004 · Cited by 137 · see citing works
Zhang, H., Wang, G., Li, J., Nie, Y., Shi, X., Lian, G., Wang, W., Yin, X., Zhao, Y., Qu, X., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.13.6938-6945.2004 · Cited by 135 · see citing works
A Label-Free Multisensing Immunosensor Based on Imaging Ellipsometry
Wang, Z. H., & Jin, G. (2003) · Analytical Chemistry · doi:10.1021/ac0347258 · Cited by 108 · see citing works
Self-citationKeng, C. T., Zhang, A., Shen, S., Lip, K.-M., Fielding, B. C., Tan, T. H. P., Chou, C.-F., Loh, C. B., Wang, S., Fu, J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3289-3296.2005 · Cited by 101 · see citing works
Real Time Analysis of Antibody‐Antigen Reaction Kinetics
Malmborg, A., Michaelsson, A., Ohlin, M., et al. (1992) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1992.tb02970.x · Cited by 100 · see citing works
Pearson, H. E., Clarke, T., Abbott, A., et al. (2003) · Nature · doi:10.1038/424121a · Cited by 90 · see citing works
Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein
Han, D. P., Kim, H. G., Kim, Y. B., et al. (2004) · Virology · doi:10.1016/j.virol.2004.05.017 · Cited by 66 · see citing works
The Ataxia Telangiectasia-Mutated and Rad3-Related Protein Is Dispensable for Retroviral Integration
DeHart, J., Andersen, J., Zimmerman, E., Ardon, O., An, D.-S., Blackett, J., Kim, B., & Planelles, V. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1389-1396.2005 · Cited by 47 · see citing works
Probing the Structure of the Sars Coronavirus Using Scanning Electron Microscopy
Lin, Y., Yan, X., Cao, W., et al. (2004) · Antiviral Therapy · doi:10.1177/135965350400900204 · Cited by 45 · see citing works
Self-citationXiao, X., Feng, Y., Chakraborti, S., & Dimitrov, D. S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.084 · Cited by 35 · see citing works
Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
Ho, T., Wu, S., Cheng, S., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.180 · Cited by 35 · see citing works
Choy, W., Shu-guang, L., Chan, P. K. S., Tam, J. S., Lo, Y. M. D., Chu, I. M., Tsai, S.-N., Zhong, M.-Q., Fung, K., Waye, M. M. Y., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.029801 · Cited by 31 · see citing works
Characterization of Murine Coronavirus Neutralization Epitopes with Phage-Displayed Peptides
Yu, M. W. N., Scott, J. K., Fournier, A., et al. (2000) · Virology · doi:10.1006/viro.2000.0310 · Cited by 31 · see citing works
Wang, Y., Li, Y., Xu, G., Dong, X., Yang, X., Feng, Z., Tian, C., & Chen, W. F. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.07.003 · Cited by 22 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- [20]O’Philippa M. BrienRobert A. Methods in molecular biology: antibody phage display (methods and protocols) 178 2002 Humana Press Totowa, New Jersey pp. 59–73 and 133–147
- [21]Borrebaeck C.A.K. Antibody engineering 1995 Oxford university press New York pp. 53–87
- [27]Dong Zh. Wang Y. Antibody engineering second ed. 2002 Peking University Medical Press Beijing pp. 308–315
- [28]Sblattero D. Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions International School for Advanced Studies Immunotechnology 3 1998 271 278 9530560
Cited by
Sorted by citations
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892 · see citing works
“Notably, the S2 regions between SARS-CoV and SARS-CoV-2 exhibit higher sequence identity (~90%) and also contain neutralizing epitopes (Duan et al., 2005; Wang et al., 2015).”
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015 · see citing works
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works
- Authors
- Duan, J., Yan, X., Guo, X., Cao, W., Han, W., Qi, C., Feng, J., Yang, D., Gao, G., & Jin, G.
- Affiliations
- Chinese Academy of Sciences (CN)
- Institute of Biophysics (CN)
- Institute of Microbiology (CN)
- Corresponding author
- Yan, Xiyun
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 333
- Issue
- 1
- Pages
- 186-193
- ISSN
- 0006-291X (ISSN-L)
- PMC
- PMC7092839
- OpenAlex
- W2109538392
- Cited by
- 114
- References
- 32
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 5 · 2022: 14 · 2021: 24 · 2020: 29 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 2 · 2013: 2 · 2012: 1
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemical and Biophysical Research Communications (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV, neutralizing antibodies, SARS-CoV spike protein, scFv, phage display, B cells, epitope mapping, pseudovirus, natural antibodies
- MeSH terms
- Antibodies, B-Lymphocytes, Humans, Immunoassay, Neutralization Tests, Viral Envelope Proteins, Epitope Mapping, Epitopes, B-Lymphocyte, Peptide Library, Severe acute respiratory syndrome-related coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
